Understanding how calcium signaling affects fatty liver disease
Dysregulation of calcium signaling in the initiation of fatty liver disease
This study is looking at how calcium levels in liver cells are affected by high-fat diets and how this might lead to non-alcoholic fatty liver disease and diabetes, with the hope of finding new ways to help people who are dealing with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11141604 on NIH RePORTER |
What this research studies
This research investigates the role of calcium signaling in the development of non-alcoholic fatty liver disease (NAFLD) and its connection to insulin resistance and type 2 diabetes. By studying the effects of high-fat diets on calcium signaling in liver cells, the research aims to uncover the molecular mechanisms that lead to impaired metabolism and disease progression. The approach involves examining how hormones like norepinephrine influence calcium levels and liver function, which could provide insights into new treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with non-alcoholic fatty liver disease or those at risk for type 2 diabetes due to obesity or metabolic syndrome.
Not a fit: Patients with alcoholic liver disease or those without metabolic disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for managing fatty liver disease and related metabolic disorders.
How similar studies have performed: Previous research has shown promising results in understanding the role of calcium signaling in metabolic diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Bartlett, Paula — Rutgers Biomedical and Health Sciences
- Study coordinator: Bartlett, Paula
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.